Fulcrum Therapeutics

#BreakingNews. Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD). “Sanofi is a proven leader in developing therapeutics for rare neuromuscular diseases and is the ideal partner to maximize the opportunity and reach of losmapimod outside the U.S.,” said Alex C. Sapir, Fulcrum’s president and chief executive officer. “This deal aligns with our core strategy, allowing Fulcrum to remain focused on preparations for commercialization of losmapimod in the U.S., while leveraging Sanofi’s exceptional global commercial capabilities and established infrastructure in key markets around the world. We are excited about the potential to provide the first approved treatment for FSHD patients, and we look forward to working with Sanofi to bring losmapimod to patients globally.” Learn more from our press release: https://ow.ly/I4jQ50REel8 #FSHD #FSHDawareness #Biotech #FulcrumTherapeutics #healthinnovations #newsalert

Get insights from Genevieve, a valued member of our Discovery Team, as she shares about the significance of working at Fulcrum and what sets us apart, making both our team and our work truly rare. #WeAreRare

#GreatNews: We’re thrilled to welcome two incredible leaders to the Fulcrum team! Isabel Kalofonos joins us as our Chief Commercial Officer, and Heather Faulds steps in as our Chief Regulatory Affairs and Quality Assurance Officer. Welcome, Isabel and Heather! Learn more about this exciting development here: https://ow.ly/FupH50T1eNC #Leadership #TeamGrowth #Fulcrum

Discover the values and background that inspired Suchi from our Discovery Team to join our DEIB Taskforce at Fulcrum. #DEIB #Culture

Darrell explains why his meaningful interactions with patients over the years have shaped his career. #PatientCentered

Fulcrum Celebrates Sickle Cell Disease Advocate Kadeem Gayle for completing his Doctorate in Medical Humanities. As students across the country gear up for a new semester to begin, we spoke with SCD Advocate Kadeem Gayle, who recently completed his Doctorate in Medical Humanities (DMH). This milestone underscores his dedication and resilience in the face of the challenges of living with a rare disease. Kadeem advises fellow students with rare diseases, particularly those starting out in a new program, to communicate openly about accommodations with professors and advisors and not to be afraid to request part-time study if needed to balance health and academic journeys. Kadeem’s degree from Drew University integrated bioethics, narrative medicine, and the human experience. His research focused on the history, origin, and bioethics of sickle cell disease, and has resulted in a compelling anthology of patient stories. Throughout his program, he faced setbacks and physical challenges head on, and his determination never wavered. Now, with his DMH, Kadeem plans to contribute to the literature, conduct further research, and potentially establish a sickle cell organization. His focus on the patient experience of pain aims to transform how healthcare workers perceive and treat sickle cell disease. Kadeem’s story is a powerful reminder of what can be achieved with perseverance, dedication, and resilience. Good luck to all in this coming semester, and congratulations on all of your accomplishments, Dr. Gayle! 

Kudos to Pam from our People Team for facilitating a panel at Leap HR Life Sciences! We’re proud to see our team members contribute to important conversations within the community. Thanks, Pam! #DEIB #FULcrew

The Sickle Cell Community never stops working for change. Here are a few of the events we have been fortunate enough to join: The 46th Jack and Jill of America, Inc. National Convention, “Your Health, Your Legacy” Health Fair was hosted in partnership with the Jaden Sebastian Blake Foundation. Attendees learned about mental, physical, and emotional health, and walk-in screenings were offered for dental health, kidney health, blood pressure, and a special focus on sickle cell disease awareness of therapies in development and general education. Pictured: Mel Hayes and Rae Blaylark, Founder and Executive Director of the Sickle Cell Foundation of Minnesota The Sickle Cell Warriors Convention, hosted by the SICKLE CELL CONSORTIUM, empowered attendees through patient-selected sessions, panels, and workshops, fostering education and support. During the event, over 100 scholarships were awarded to warriors and caregivers, including nearly 90 full scholarships. Pictured: Mel Hayes, William Engelman, MD

At Fulcrum, it is always a privilege to meet the people we serve. Our recent All-Hands meeting offered one of those opportunities with FSHD patient advocate William Sarraille. Bill is a nationally recognized healthcare policy expert and a true inspiration to all of us at Fulcrum. Bill was diagnosed with muscular dystrophy in his third year of law school. At the time, his doctor wasn’t sure whether it was FSHD or limb girdle, but the doctor was sure that there would not be a treatment available in Bill’s lifetime. So Bill set his diagnosis aside and put all of his energy into his work—healthcare law. Being diagnosed with a rare disease himself gave Bill a passion for helping patients with other rare diseases secure access to treatments, but that didn’t translate into a focus on FSHD. Late in his career, though, things started to change. Some of Bill’s associates were rare disease patients themselves, and they were much more open about their conditions. Learning about the work that companies like Fulcrum were doing to potentially bring treatments to market, and the FSHD Society’s work to help build an FSHD research “ecosystem,”  Bill was motivated to turn his healthcare expertise towards the disease that his family has struggled with for five generations. In his 30+ years practicing law, Bill helped numerous rare disease patient groups, drug developers, and others—shepherding rare disease treatments through the coverage and reimbursement pathway. Though Bill is now retired from his law practice, he is now working in a number of roles, including helping the FSHD Society, as a board member, to support the efforts of research leaders. Bill has achieved so much while living with FSHD—balancing a demanding career while navigating health challenges, all while working tirelessly to improve the lives of rare disease patients. Thank you, Bill, for sharing your story with us. Pictured: Alex Sapir, Bill Sarraille #fshdawareness #raredisease

As the CEO at Fulcrum, Alex is keenly focused on ensuring the FULcrew is connected with each other and the broader community. Discover why this value is so important to him. #CoreValues #WeAreRare